A critical review of the cannabinoid receptor as a drug target for obesity management.

摘要: The discovery of cannabinoids, with the well-known stimulatory effect Cannabis sativa on appetite, has offered a new drug target for obesity treatment. Cannabinoids act two different receptors: CB1 receptors which are sited in brain and many peripheral tissues, CB2 primarily found immune system cells. Cannabinoid receptor antagonists centrally by blocking receptors, thereby reducing food intake. Moreover, they probably also peripherally increasing thermogenesis therefore energy expenditure, as been suggested animal experiments. Despite these promising mechanisms action, recent clinical studies examining rimonabant taranabant showed that attained weight loss did not exceed other currently approved anti-obesity medications. potentially severe psychiatric adverse effects limit their use. As several presently undergoing development, it remains to be elucidated what extent differ terms efficacy safety. This review discusses how close cannabinoid ideal drug, respect effectiveness